$ERNA
Eterna Therapeutics Inc.

2022 Q4 Form 10-Q Financial Statement

#000114036122041399 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.780M $3.340M $4.209M
YoY Change -33.95% -21.56% 212.23%
% of Gross Profit
Research & Development $1.960M $4.963M $4.326M
YoY Change -54.69% 238.39%
% of Gross Profit
Depreciation & Amortization $20.00K $40.00K $24.25K
YoY Change -17.53% 36.71% -92.15%
% of Gross Profit
Operating Expenses $4.740M $8.304M $9.285M
YoY Change -48.95% 466.19% 582.71%
Operating Profit -$8.304M
YoY Change -90.38%
Interest Expense -$10.00K -$20.00K -$18.03K
YoY Change -44.54% -1.04%
% of Operating Profit
Other Income/Expense, Net $300.0K $993.0K $664.6K
YoY Change -54.86% 258.39% -37.42%
Pretax Income -$4.450M -$7.311M -$8.638M
YoY Change -48.48% -91.5% -2766.06%
Income Tax $40.00K $5.000K $64.00K
% Of Pretax Income
Net Earnings -$4.500M -$7.300M -$8.702M
YoY Change -48.29% -91.52% -2934.54%
Net Earnings / Revenue
Basic Earnings Per Share -$2.49
Diluted Earnings Per Share -$1.24 -$2.49 -$166.9K
COMMON SHARES
Basic Shares Outstanding 2.942M 58.83M 52.04M
Diluted Shares Outstanding 2.941M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.45M $13.25M $16.99M
YoY Change -32.59% -45.66% 2085.97%
Cash & Equivalents $11.45M $13.25M $16.99M
Short-Term Investments
Other Short-Term Assets $1.280M $1.670M $1.097M
YoY Change 16.68% 23.41% 32.01%
Inventory
Prepaid Expenses
Receivables $950.0K $684.0K
Other Receivables $951.0K $926.0K $684.0K
Total Short-Term Assets $13.68M $15.85M $18.77M
YoY Change -27.1% -38.46% 983.49%
LONG-TERM ASSETS
Property, Plant & Equipment $236.0K $231.0K $670.0K
YoY Change -64.78% -94.52% 12.79%
Goodwill $2.000M $2.000M $2.044M
YoY Change -2.15% -2.14% 0.0%
Intangibles
YoY Change
Long-Term Investments $59.00K $68.00K $1.000M
YoY Change -94.1% -93.2%
Other Assets $1.134M $819.0K $488.0K
YoY Change 132.38% 300.0%
Total Long-Term Assets $8.598M $5.074M $12.76M
YoY Change -32.61% -62.79% 5.94%
TOTAL ASSETS
Total Short-Term Assets $13.68M $15.85M $18.77M
Total Long-Term Assets $8.598M $5.074M $12.76M
Total Assets $22.28M $20.93M $31.53M
YoY Change -29.33% -46.88% 128.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.620M $1.150M $1.755M
YoY Change -7.69% 15.43% 37.65%
Accrued Expenses $3.626M $3.230M $1.249M
YoY Change 190.31% 51.75% 18.84%
Deferred Revenue
YoY Change
Short-Term Debt $1.750M $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $7.654M $7.467M $3.677M
YoY Change 108.16% 63.73% 17.66%
LONG-TERM LIABILITIES
Long-Term Debt $1.210M $10.00K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $94.00K $1.690M $48.00K
YoY Change 95.83% -92.25% 108.7%
Total Long-Term Liabilities $94.00K $1.690M $48.00K
YoY Change 95.83% -92.25% 108.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.654M $7.467M $3.677M
Total Long-Term Liabilities $94.00K $1.690M $48.00K
Total Liabilities $10.17M $12.11M $6.022M
YoY Change 68.91% -54.04% -76.25%
SHAREHOLDERS EQUITY
Retained Earnings -$165.3M -$160.8M -$140.7M
YoY Change 17.48% 6.33% 276.4%
Common Stock $26.00K $15.00K $260.0K
YoY Change -90.0% -94.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.11M $8.813M $25.50M
YoY Change
Total Liabilities & Shareholders Equity $22.28M $20.93M $31.53M
YoY Change -29.33% -46.88% 128.84%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$4.500M -$7.300M -$8.702M
YoY Change -48.29% -91.52% -2934.54%
Depreciation, Depletion And Amortization $20.00K $40.00K $24.25K
YoY Change -17.53% 36.71% -92.15%
Cash From Operating Activities -$5.440M -$6.110M -$6.830M
YoY Change -20.36% -4.87% 1012.44%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $50.00K -$147.1K
YoY Change -113.59% -828.86% 104.36%
Acquisitions
YoY Change
Other Investing Activities $150.0K $0.00 -$250.00
YoY Change -60100.0% -100.0% -100.02%
Cash From Investing Activities $130.0K -$50.00K -$147.4K
YoY Change -188.2% -99.78% -112.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.590M 10.00K -418.6K
YoY Change -1913.1% -99.71% -71.6%
NET CHANGE
Cash From Operating Activities -5.440M -6.110M -6.830M
Cash From Investing Activities 130.0K -50.00K -147.4K
Cash From Financing Activities 7.590M 10.00K -418.6K
Net Change In Cash 2.280M -6.150M -7.396M
YoY Change -130.83% -76.15% 691.9%
FREE CASH FLOW
Cash From Operating Activities -$5.440M -$6.110M -$6.830M
Capital Expenditures $20.00K $50.00K -$147.1K
Free Cash Flow -$5.460M -$6.160M -$6.683M
YoY Change -18.3% -3.99% 1133.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Goodwill
Goodwill
2044000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3677000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
169596000
CY2022Q3 us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
8000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7316000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-85986000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
us-gaap Net Income Loss
NetIncomeLoss
-114593000
CY2022Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
CY2021Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
8000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7316000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-85986000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20098000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-114601000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-34.03
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-34.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-56.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-56.79
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2941000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2941000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2527000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2527000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2855000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2018000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
772000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
5990000
us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
8000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-style: italic;">Reclassifications</span><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Certain reclassifications have been made to Eterna’s prior years’ financial statements to conform to the current year presentation. These reclassifications had no effect on Eterna’s previously reported results of operations or accumulated deficit.</div>
dei Security12b Title
Security12bTitle
Common stock, $0.005 par value per share
dei Trading Symbol
TradingSymbol
ERNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
2942120
CY2022Q3 us-gaap Cash
Cash
13254000
CY2021Q4 us-gaap Cash
Cash
16985000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
926000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
684000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1672000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1097000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
15852000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
18766000
CY2022Q3 us-gaap Goodwill
Goodwill
2044000
CY2022Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1249000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2648000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
247000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7467000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
243000
us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
0
us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
5765000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-9648000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
237000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11986000
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
0
us-gaap Proceeds From Sales Of Assets Investing Activities
ProceedsFromSalesOfAssetsInvestingActivities
147000
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62004000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3731000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24383000
us-gaap Interest Paid Net
InterestPaidNet
25000
us-gaap Interest Paid Net
InterestPaidNet
13000
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
8177000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0000748592
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-11460
dei Entity Registrant Name
EntityRegistrantName
Eterna Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1103425
dei Entity Address Address Line1
EntityAddressAddressLine1
10355 Science Center Drive, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
582-1199
dei Entity Information Former Legal Or Registered Name
EntityInformationFormerLegalOrRegisteredName
Brooklyn ImmunoTherapeutics, Inc.
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
231000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
670000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1912000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2567000
CY2021Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5990000
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
68000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
1000000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
819000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
488000
CY2022Q3 us-gaap Assets
Assets
20926000
CY2021Q4 us-gaap Assets
Assets
31525000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1150000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1755000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3230000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
426000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
633000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2317000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2297000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
6000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1690000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
48000
CY2022Q3 us-gaap Liabilities
Liabilities
12113000
CY2021Q4 us-gaap Liabilities
Liabilities
6022000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2021Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2022Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2942000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2942000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2601000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2601000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
15000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
166190000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160799000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140701000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8813000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25503000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20926000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31525000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4963000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1491000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8430000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8456000
CY2022Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
80538000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5990000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
80538000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3341000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4247000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14060000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10451000
CY2021Q3 us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
0
us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
0
us-gaap Noncash Merger Related Costs
NoncashMergerRelatedCosts
5765000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8304000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
86276000
us-gaap Operating Expenses
OperatingExpenses
28480000
us-gaap Operating Expenses
OperatingExpenses
105210000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8304000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-86276000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28480000
us-gaap Operating Income Loss
OperatingIncomeLoss
-105210000
CY2022Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2021Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-9648000
CY2022Q3 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-1024000
CY2021Q3 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
0
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-10493000
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
0
CY2022Q3 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
21000
CY2021Q3 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
932000
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1166000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
265000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
993000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
290000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8395000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9383000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7311000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-85986000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20085000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-114593000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2855000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2018000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
14778000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2022Q3 erna Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
875000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
476000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7316000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8813000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25503000
erna Stock Issued During Period Value Private Offering
StockIssuedDuringPeriodValuePrivateOffering
0
erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-5000
erna Stock Issued During Period Value Exercise Of Pre Funded Warrants
StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants
875000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2538000
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
8000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8813000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53603000
CY2021Q3 erna Common Stock To Be Retained By Ntn Value Stockholders
CommonStockToBeRetainedByNTNValueStockholders
0
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2021Q3 erna Stock Issued During Period Value Stock Purchase Agreement
StockIssuedDuringPeriodValueStockPurchaseAgreement
3500000
CY2021Q3 erna Stock Issued During Period Value In Lieu Of Dividends
StockIssuedDuringPeriodValueInLieuOfDividends
0
CY2021Q3 erna Stock Issued During Period Value Acquisitions2
StockIssuedDuringPeriodValueAcquisitions2
58684000
CY2021Q3 erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1729000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-85986000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31530000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7659000
erna Stock Issued During Period Value Rights Offering Membership Units
StockIssuedDuringPeriodValueRightsOfferingMembershipUnits
10500000
erna Adjustments To Additional Paid In Capital Elimination Historical Member Equity
AdjustmentsToAdditionalPaidInCapitalEliminationHistoricalMemberEquity
0
erna Stock Issued During Period Value Acquisitions1
StockIssuedDuringPeriodValueAcquisitions1
8177000
erna Stock Issued During Period Value New Issues Of Preferred Stock Retained By Stockholders
StockIssuedDuringPeriodValueNewIssuesOfPreferredStockRetainedByStockholders
0
us-gaap Partners Capital Account Acquisitions
PartnersCapitalAccountAcquisitions
0
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
5765000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
erna Stock Issued During Period Value Stock Purchase Agreement
StockIssuedDuringPeriodValueStockPurchaseAgreement
52026000
erna Stock Issued During Period Value In Lieu Of Dividends
StockIssuedDuringPeriodValueInLieuOfDividends
0
erna Stock Issued During Period Value Acquisitions2
StockIssuedDuringPeriodValueAcquisitions2
58684000
erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3302000
us-gaap Net Income Loss
NetIncomeLoss
-114593000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
31530000
us-gaap Net Income Loss
NetIncomeLoss
-20090000
us-gaap Net Income Loss
NetIncomeLoss
-114593000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
144000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
93000
us-gaap Share Based Compensation
ShareBasedCompensation
2538000
us-gaap Share Based Compensation
ShareBasedCompensation
3302000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
267000
erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
0
erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
80538000
erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
431000
erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
13000
erna Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
0
erna Gain Loss On Forgiveness Of Paycheck Protection Program Loan
GainLossOnForgivenessOfPaycheckProtectionProgramLoan
310000
erna Gain On Termination Of Lease
GainOnTerminationOfLease
85000
erna Gain On Termination Of Lease
GainOnTerminationOfLease
0
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-10493000
erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
0
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
932000
erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
0
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-5000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
575000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1109000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
331000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
31000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1376000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-196000
erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-223000
erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-226000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4043000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
202000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15541000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16656000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
276000
erna Payments To Acquire Productive Assets Net
PaymentsToAcquireProductiveAssetsNet
0
erna Payments To Acquire Productive Assets Net
PaymentsToAcquireProductiveAssetsNet
22854000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
119000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-176000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22595000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11993000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
-7000
erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
0
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
erna Proceeds From Issuance Of Common Stock To Lincoln Park
ProceedsFromIssuanceOfCommonStockToLincolnPark
0
erna Proceeds From Issuance Of Common Stock To Lincoln Park
ProceedsFromIssuanceOfCommonStockToLincolnPark
54106000
erna Fees Incurred In Connection With The Common Stock Issued To Lincoln Park
FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark
0
erna Fees Incurred In Connection With The Common Stock Issued To Lincoln Park
FeesIncurredInConnectionWithTheCommonStockIssuedToLincolnPark
2080000
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
10500000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
erna Payments Of Paycheck Protection Program Loan
PaymentsOfPaycheckProtectionProgramLoan
0
erna Payments Of Paycheck Protection Program Loan
PaymentsOfPaycheckProtectionProgramLoan
532000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22753000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16985000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1630000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13254000
erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
867000
erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
0
erna Issuance Of Common Stock For Series A Preferred Stock Dividend
IssuanceOfCommonStockForSeriesAPreferredStockDividend
0
erna Issuance Of Common Stock For Series A Preferred Stock Dividend
IssuanceOfCommonStockForSeriesAPreferredStockDividend
8000
erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
0
erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
58684000
erna Noncash Or Part Noncash Acquisition Preferred Shares Issued In Connection With Reverse Merger
NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
0
erna Noncash Or Part Noncash Acquisition Preferred Shares Issued In Connection With Reverse Merger
NoncashOrPartNoncashAcquisitionPreferredSharesIssuedInConnectionWithReverseMerger
1000
erna Initial Measurement Of Right Of Use Assets And Liabilities
InitialMeasurementOfRightOfUseAssetsAndLiabilities
1706000
erna Initial Measurement Of Right Of Use Assets And Liabilities
InitialMeasurementOfRightOfUseAssetsAndLiabilities
816000
erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
1706000
erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
866000
erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
10000
erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2022Q3 erna Cash Paid For Fractional Shares In Connection With Reverse Stock Split
CashPaidForFractionalSharesInConnectionWithReverseStockSplit
719
CY2022Q3 erna Number Of Shares Considered As Fractional In Reverse Stock
NumberOfSharesConsideredAsFractionalInReverseStock
175
CY2022Q3 us-gaap Cash
Cash
13300000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160800000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7300000
us-gaap Net Income Loss
NetIncomeLoss
-20100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15500000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
12600000
CY2022Q3 erna Over Subscription Amount Received
OverSubscriptionAmountReceived
600000
CY2022Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
12000000
CY2022Q3 erna Over Subscription Amount Received
OverSubscriptionAmountReceived
600000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
12589000
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-11089000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
867000
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
633000
CY2022Q3 erna Operating Lease Area
OperatingLeaseArea
5200
CY2022Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P62M
erna Base Rent Per Square Foot
BaseRentPerSquareFoot
6.35
CY2022Q3 erna Percentage Base Rent Increase On Each Anniversary
PercentageBaseRentIncreaseOnEachAnniversary
0.03
CY2022Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
1700000
erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
1700000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
800000
CY2022Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
-0
CY2022Q1 erna Lessee Commitment To Purchase Property
LesseeCommitmentToPurchaseProperty
50000
CY2022Q1 erna Unamortized Leasehold Improvements
UnamortizedLeaseholdImprovements
50000
CY2022Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
63000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
143000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
187000
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
21000
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
21000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
60000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
6000
CY2022Q3 us-gaap Lease Cost
LeaseCost
182000
CY2021Q3 us-gaap Lease Cost
LeaseCost
172000
us-gaap Operating Lease Cost
OperatingLeaseCost
476000
us-gaap Operating Lease Cost
OperatingLeaseCost
501000
us-gaap Sublease Income
SubleaseIncome
63000
us-gaap Sublease Income
SubleaseIncome
62000
us-gaap Variable Lease Cost
VariableLeaseCost
113000
us-gaap Variable Lease Cost
VariableLeaseCost
16000
us-gaap Lease Cost
LeaseCost
526000
us-gaap Lease Cost
LeaseCost
455000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2567000
erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
1706000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
267000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
772000
erna Remeasurement Of Operating Lease Right Of Use Asset
RemeasurementOfOperatingLeaseRightOfUseAsset
50000
erna Write Off Of Operating Lease Right Of Use Asset
WriteOffOfOperatingLeaseRightOfUseAsset
1372000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1912000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2723000
erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
1706000
erna Principal Payments On Operating Lease Liabilities
PrincipalPaymentsOnOperatingLeaseLiabilities
223000
erna Write Off Of Operating Lease Liability
WriteOffOfOperatingLeaseLiability
1453000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2752000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2317000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0897
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
166000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
673000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
688000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
703000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
708000
CY2022Q3 erna Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
470000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3408000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
656000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2752000
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
6000000
CY2022Q3 us-gaap Goodwill
Goodwill
2000000
CY2022Q2 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
6000000
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2022Q2 us-gaap Share Price
SharePrice
10.4
CY2022Q3 us-gaap Share Price
SharePrice
4.94
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1701000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
656000
CY2022Q3 erna Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
373000
CY2021Q4 erna Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
222000
CY2022Q3 erna Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
1156000
CY2021Q4 erna Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
371000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3230000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1249000
CY2022Q3 erna Current Portion Of License Fee Obligation
CurrentPortionOfLicenseFeeObligation
1750000
CY2021Q4 erna Current Portion Of License Fee Obligation
CurrentPortionOfLicenseFeeObligation
0
CY2022Q3 erna Insurance Policy Premiums
InsurancePolicyPremiums
898000
CY2021Q4 erna Insurance Policy Premiums
InsurancePolicyPremiums
247000
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2648000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
247000
CY2022Q3 erna Long Term Portion Of License Fee Obligation
LongTermPortionOfLicenseFeeObligation
1642000
CY2021Q4 erna Long Term Portion Of License Fee Obligation
LongTermPortionOfLicenseFeeObligation
0
CY2022Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
48000
CY2021Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
48000
CY2022Q3 us-gaap Other Liabilities
OtherLiabilities
1690000
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
48000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
600000
CY2022Q3 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
1200000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
476000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1729000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2538000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3302000
CY2021Q1 erna Stock Issued During Period Shares Acquisitions1
StockIssuedDuringPeriodSharesAcquisitions1
53000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
722000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
722000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
193000
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
193000

Files In Submission

Name View Source Status
0001140361-22-041399-index-headers.html Edgar Link pending
0001140361-22-041399-index.html Edgar Link pending
0001140361-22-041399.txt Edgar Link pending
0001140361-22-041399-xbrl.zip Edgar Link pending
brhc10043851_10q.htm Edgar Link pending
brhc10043851_ex10-3.htm Edgar Link pending
brhc10043851_ex31-1.htm Edgar Link pending
brhc10043851_10q_htm.xml Edgar Link completed
brhc10043851_ex31-2.htm Edgar Link pending
brhc10043851_ex32-1.htm Edgar Link pending
brhc10043851_ex32-2.htm Edgar Link pending
erna-20220930.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00001.jpg Edgar Link pending
img001_v1.jpg Edgar Link pending
img002_v1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
erna-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
erna-20220930_cal.xml Edgar Link unprocessable
erna-20220930_def.xml Edgar Link unprocessable
erna-20220930_pre.xml Edgar Link unprocessable